Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Uncontrolled cancer cell proliferation necessitates targeted therapies like small-molecule inhibitors.
• Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib, target the G1 phase of the cell cycle.
• CDK4/6 inhibitors are FDA-approved for ER-positive/HER2-negative breast cancer, with ongoing trials in other cancers.

Purpose of the Study:

• To review preclinical studies supporting combination therapies involving CDK4/6 inhibitors.
• To discuss the rationale for combining CDK4/6 inhibitors with immune checkpoint blockade agents.
• To explore the impact of CDK4/6 inhibitors on tumor-infiltrating lymphocytes.

Main Methods:

• Review of recent preclinical studies on CDK4/6 inhibitor combinations.
• Analysis of studies investigating the effects of CDK4/6 inhibitors on immune cells within tumors.
• Examination of treatment schedules for combination therapies.

Main Results:

• Preclinical data support the use of CDK4/6 inhibitors in combination regimens.
• CDK4/6 inhibitors can influence the tumor microenvironment, potentially enhancing immunotherapy.
• Resistance to CDK4/6 inhibitors is a significant clinical challenge.

Conclusions:

• Combination strategies including CDK4/6 inhibitors are being investigated to overcome resistance and improve outcomes.
• Targeting CDK4/6 in conjunction with immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) presents a promising therapeutic avenue.
• Understanding CDK4/6 inhibitor effects on tumor-infiltrating lymphocytes is crucial for optimizing combination therapy design.